A warm and humid double response sanitary comfortable pain functional chip and sanitary towel

Abstract

This invention discloses a temperature and humidity-responsive sanitary napkin and a sanitary napkin. The sanitary napkin includes a substrate and temperature and humidity-sensitive microcapsules loaded on the substrate. The temperature and humidity-sensitive microcapsules include a core material and a wall material surrounding the core material. The wall material is a composite material of acrylic resin and poly(N-isopropylacrylamide). The core material includes functional components. This invention, by setting the temperature and humidity-sensitive microcapsules with a cross-linked composite wall material, enables them to synergistically respond and release medication within body temperature ranges and under localized hot and humid conditions, thereby achieving active triggering release during premenstrual and menstrual periods, avoiding dependence on menstrual blood contact conditions, and improving the timeliness and applicability of pain relief care. This invention, by designing the sanitary napkin with a self-contained layered structure, prevents the functional chip from participating in the main spinning and high-temperature hot rolling processes, effectively avoiding premature deactivation of the microcapsules and functional components during the main processing.

Description

Technical Field

[0001] This invention belongs to the field of feminine hygiene products technology, specifically relating to a sanitary napkin with a dual temperature and humidity response for pain relief. Background Technology

[0002] Dysmenorrhea is a common menstrual-related discomfort symptom among women of childbearing age, characterized by high incidence, long duration, and wide impact. Clinical and daily usage scenarios indicate that dysmenorrhea can manifest not only as abdominal pain during menstruation but also during the premenstrual or postmenstrual phase. Premenstrual dysmenorrhea, because menstrual blood has not yet appeared, is often difficult for traditional menstrual care products to recognize and trigger their corresponding functions, resulting in a lack of timely and effective intervention for affected individuals. Therefore, how to ensure that feminine hygiene products can provide stable and effective pain relief throughout the continuous cycle from premenstrual to menstruation has become a pressing technical problem to be solved in this field.

[0003] Currently, most feminine hygiene products on the market with pain-relieving or conditioning functions are based on the structure of conventional hygiene products with added functional ingredient layers, coating layers, or aromatherapy slow-release layers, aiming to alleviate abdominal discomfort to some extent during use. However, existing technologies still have significant shortcomings overall.

[0004] Firstly, the functional release mechanism of some products is highly dependent on menstrual blood contact, liquid penetration, or specific usage conditions. This often makes it difficult to activate the product in time during the premenstrual period when there is no menstrual flow, resulting in an incomplete care cycle and failing to meet the actual needs of those experiencing premenstrual dysmenorrhea. Furthermore, functional ingredients directly attached to or coated on the surface of sanitary products are prone to volatilization, migration, or adsorption by the underlying absorption structure during storage, processing, or use, leading to low utilization of active ingredients, short duration of action, and slow onset of action. Secondly, the spinning, hot rolling, lamination, and drying processes in sanitary product manufacturing typically involve high temperatures. If functional materials are directly involved in the main processing, the microcapsule wall material is prone to softening, rupture, leakage, or premature deactivation of active ingredients, thus affecting the final efficacy and mass production stability of the product. Thirdly, if the functional layer is integrated with the absorbent core or flow-guiding structure, the released functional ingredients tend to migrate downwards and be trapped by the absorbent core, making it difficult to achieve targeted action towards the skin. This not only reduces the actual efficiency of action but also weakens the targeted care effect on the painful area.

[0005] Furthermore, existing products primarily utilize general soothing, cooling, or mild health-promoting ingredients in their functional formulations. These often suffer from slow onset, weak effects, and insufficient duration of action in relieving uterine smooth muscle spasms, alleviating local cold-induced discomfort, inhibiting pain signal transmission, and regulating premenstrual syndrome. This makes it difficult to meet the needs of users with moderate to severe dysmenorrhea who require rapid relief and continuous care. Simultaneously, the functional structures of existing products are largely integrated with the main sanitary product, making it difficult to independently prepare, test, and die-cut functional modules during production. This hinders segmented process control, consistent quality management, and large-scale industrial implementation. Therefore, current technology lacks a sanitary pain-relieving functional structure that can be actively triggered in the absence of menstrual blood before menstruation, while also ensuring the stability of functional ingredients, targeted release effects, sustained soothing capabilities, and industrial compatibility. Summary of the Invention

[0006] The purpose of this invention is to provide a sanitary napkin with a dual temperature and humidity response function for pain relief.

[0007] In a first aspect, the present invention provides a temperature and humidity-responsive sanitary analgesia functional chip, comprising a substrate and temperature and humidity-sensitive microcapsules loaded on the substrate; the temperature and humidity-sensitive microcapsules comprising a core material and a wall material surrounding the core material; the wall material being a composite material of acrylic resin and poly(N-isopropylacrylamide); the core material comprising functional components.

[0008] Preferably, the core material further includes a phase change material. The phase change temperature range of the phase change material is 32–38°C.

[0009] Preferably, the core material further includes a transdermal penetration enhancer; the transdermal penetration enhancer includes menthol and laurocapram. The functional components include Corydalis extract, cinnamon extract, Paeonia lactiflora extract, Angelica sinensis extract and Leonurus japonicus extract in a mass ratio of (15-20):(12-18):(10-15):(8-12):(5-10).

[0010] Preferably, the acrylic resin and poly(N-isopropylacrylamide) in the wall material form a three-dimensional cross-linked network through a cross-linking agent.

[0011] Preferably, the sanitary pain relief chip further includes a breathable, skin-friendly contact layer and an anti-migration isolation layer. The substrate is disposed between the breathable, skin-friendly contact layer and the anti-migration isolation layer. The substrate has temperature and humidity sensitive microcapsules on only the side near the breathable, skin-friendly contact layer, or on both sides.

[0012] Secondly, the present invention provides a preparation method for preparing the aforementioned sanitary analgesia functional chip.

[0013] The preparation method includes:

[0014] Preparation of core material premix: The freeze-dried powders of Corydalis extract, cinnamon extract, white peony extract, angelica extract and motherwort extract are mixed in a preset ratio, an oleophilic auxiliary is added, and after cooling, they are mixed with phase change material and transdermal accelerator to obtain core material premix.

[0015] Preparation of temperature and humidity sensitive microcapsules: An aqueous phase system was prepared using polyvinyl alcohol and sodium dodecyl sulfate, and an oil phase system was prepared using methyl acrylate monomer, N-isopropylacrylamide monomer, divinylbenzene, azobisisobutyronitrile, and a core material premix. The oil phase system was added dropwise to the aqueous phase system to form an emulsion, and the mixture was heated to carry out a polymerization reaction. Nitrogen gas was continuously introduced during the polymerization reaction. After polymerization, the microcapsules were cooled, centrifuged, washed, and vacuum dried to obtain the temperature and humidity sensitive microcapsules.

[0016] Preparation of coating stock solution: Mix the temperature and humidity sensitive microcapsules, aqueous adhesive, skin-friendly additive and deionized water to obtain the coating stock solution;

[0017] Preparation of functional chip roll material: The coating masterbatch is coated on the surface of the substrate, dried, cooled and then rolled up to obtain the functional chip roll material;

[0018] Functional chip molding: Processing functional chip rolls into pre-defined shapes for sanitary pain relief functional chips.

[0019] Preferably, the lipophilic agent is glyceryl monostearate or beeswax; the amount of the lipophilic agent is 8% to 10% of the total mass of each extract; after adding the lipophilic agent, the mixture is stirred at 55 to 65°C.

[0020] Preferably, during the droplet addition of the oil phase system to the aqueous phase system, an emulsion with a median particle size D50 of 1–3 μm is formed through shear emulsification. The aqueous binder is hydroxypropyl methylcellulose, and the skin-friendly additive is glyceryl monostearate.

[0021] Thirdly, the present invention provides a sanitary product, characterized in that it comprises a sanitary product body and a sanitary pain relief functional chip installed within the sanitary product. The sanitary product body is any one of a sanitary napkin, panty liner, menstrual underwear, or uterine warming patch. In the usage state, the sanitary product has the sanitary pain relief functional chip positioned aligned with the lower abdomen.

[0022] Fourthly, a sanitary napkin includes a surface layer, a diversion layer, an absorbent core, a leak-proof layer, a bottom film layer, and the sanitary napkin pain-relieving functional chip as described in claim 4; the surface layer, diversion layer, absorbent core, leak-proof layer, and bottom film layer are sequentially stacked, and the sanitary napkin pain-relieving functional chip is disposed between the surface layer and the diversion layer. The anti-migration isolation layer is located on the side of the substrate near the diversion layer, and the breathable and skin-friendly contact layer is located on the side of the substrate near the surface layer.

[0023] The present invention has the following beneficial effects.

[0024] 1. This invention designs the sanitary pain relief functional chip as an independent layered structure and places it between the surface layer and the flow guide layer of the sanitary product. This prevents the functional chip from participating in the main processes of spinning and high-temperature hot rolling, thereby effectively avoiding the premature deactivation of microcapsules and functional ingredients during the main processing and improving product stability and process compatibility.

[0025] 2. This invention utilizes thermo- and humidity-sensitive microcapsules in PMA-PNIPAM composite wall materials to enable synergistic responses and drug release within body temperature ranges and localized humid and hot environments. This achieves active triggering and release during premenstrual and menstrual periods, avoiding dependence on menstrual blood contact conditions and improving the timeliness and applicability of pain relief care.

[0026] 3. This invention combines phase change materials, functional components, transdermal penetration enhancers, and lipophilic agents in the core material, along with a compound formulation system that provides pain relief, uterine warming, antispasmodic effects, blood circulation promotion, and menstrual regulation. This results in rapid onset of action, synergistic effects, and sustained relief, enhancing the overall relief effect on dysmenorrhea and related discomfort symptoms.

[0027] 4. This invention employs low-temperature water extraction and freeze-drying, core material oleophilic pretreatment, interfacial polymerization to prepare microcapsules, and low-temperature coating and curing molding processes to balance the activity of traditional Chinese medicine extracts, the integrity of microcapsules, and the uniformity of finished product loading, thereby improving the controllability of functional chip preparation, the stability of mass production, and the reliability of long-term storage.

[0028] 5. This invention, by setting a breathable and skin-friendly contact layer and an anti-migration isolation layer, and constructing a layered guiding structure that releases towards the skin, ensures a lightweight, breathable, soft, and low-irritation user experience while reducing the migration loss of functional ingredients to the absorbent core, thereby improving the targeted utilization rate of functional ingredients and the actual care effect. Attached Figure Description

[0029] Figure 1 This is a schematic diagram of the structure of the pain relief chip for hygiene provided in Embodiment 1 of the present invention.

[0030] Figure 2 This is a schematic diagram of the internal structure of the temperature and humidity sensitive microcapsule in Embodiment 1 of the present invention.

[0031] Figure 3 This is a flowchart of the preparation method provided in Embodiment 2 of the present invention.

[0032] Figure 4 This is a schematic diagram of the structure of the pain relief chip for hygiene provided in Embodiment 3 of the present invention.

[0033] Figure 5This is an exploded view of the sanitary napkin provided in Embodiment 4 of the present invention.

[0034] Figure 6 This is an exploded view of the sanitary napkin provided in Embodiment 5 of the present invention.

[0035] Reference numerals: 100, substrate; 200, temperature and humidity sensitive microcapsule; 210, wall material; 220, core material; 300, breathable and skin-friendly contact layer; 400, anti-migration isolation layer; 500, surface layer; 600, diversion layer; 700, absorbent core; 800, anti-seepage layer; 900, bottom membrane layer. Detailed Implementation

[0036] The present invention will be further described below with reference to the accompanying drawings.

[0037] To make the technical solution of the present invention clearer and more complete, the present invention will be further described below in conjunction with specific embodiments. It should be understood that the following embodiments are only used to illustrate the present invention and are not intended to limit the scope of protection of the present invention.

[0038] Example 1

[0039] A temperature and humidity responsive sanitary analgesia chip, employing an independent layered structure, is positioned between the surface layer 500 and the guide layer 600 of a sanitary product. It does not participate in the main spinning and high-temperature hot rolling processes, thus preventing premature deactivation of the functional components during the main sanitary product processing. The sanitary analgesia chip provided in this embodiment can be applied to products such as sanitary napkins, panty liners, menstrual underwear, and uterine warming patches, preferably positioned in the corresponding uterine area. The sanitary analgesia chip is an independently cut flexible sheet structure, with an overall thickness preferably not exceeding 0.3 mm, ensuring that the functional layer functions independently without significantly affecting the softness, fit, and wearing comfort of the sanitary product itself.

[0040] like Figure 1 As shown, the sanitary analgesia functional chip includes a substrate 100 and a thermo- and humidity-sensitive microcapsule 200. The thermo- and humidity-sensitive microcapsule 200 is loaded on the substrate 100 and performs the core function of relieving pain. The substrate 100 uses a pH of 12-25 g / m³. 2 The substrate 100 is a pure white hot air nonwoven fabric. The thickness of the substrate 100 is no more than 0.3 mm. In some embodiments, the basis weight of the substrate 100 is preferably 18-22 g / m2, more preferably 20 g / m2, to balance microcapsule load, air permeability and softness.

[0041] In this embodiment, the ES white hot air nonwoven fabric used as the substrate 100 has the following advantages: (1) uniform surface, fine fibers, skin-friendly and non-irritating; (2) high air permeability, ensuring dryness and no stuffiness during use; (3) moderate stiffness, which is convenient for coating, lamination, die cutting and high-speed production line; (4) no shedding, no migration and no back seepage, ensuring product cleanliness; (5) sufficient raw material supply, controllable cost, and suitable for large-scale stable production.

[0042] like Figure 2 As shown, the thermo- and humidity-sensitive microcapsule 200 includes a wall material 210 and a core material 220. The wall material 210 wraps around the core material 220. The wall material 210 is a PMA-PNIPAM composite material, namely a composite material of polymethyl acrylate and poly(N-isopropylacrylamide) (PNIPAM). In some other embodiments, the polymethyl acrylate can be replaced with other acrylic resins. PNIPAM provides thermo-sensitive response within the body temperature range, while PNIPAM provides humidity-sensitive swelling and structural support. The core material 220 contains functional components that achieve pain relief.

[0043] The material properties of the wall material 210 enable the temperature and humidity sensitive microcapsule 200 to exhibit a temperature-sensitive response at 32-38°C and a humidity-sensitive response when the local humidity is greater than or equal to 55%RH. The synergistic effect of the two causes the microcapsule wall material 210 to open and release the core material 220.

[0044] In some embodiments, the median particle size D50 of the temperature and humidity sensitive microcapsules 200 is 1.0–3.0 μm; the wall material 210 has a thickness of 150 nm–250 nm, a core-shell ratio of (2–3):1, a drug loading of 40%–55% by mass, a response time of 30 s–3 min, a moisture content of less than or equal to 3.0%, and good flowability (i.e., a free-flowing powder appearance without clumping). The wall material 210 thickness range of 150 nm–250 nm balances the heat resistance and response sensitivity of the wall material 210. Excessive thickness leads to decreased response sensitivity, while insufficient thickness easily results in capsule rupture. An excessively high core-shell ratio leads to incomplete encapsulation by the wall material 210, while an excessively low core-shell ratio results in insufficient drug loading, failing to meet the efficacy requirements during menstruation. A drug loading of 40%–55% by mass ensures that the microcapsules possess sufficient functional components to meet the requirement of continuous release for more than 8 hours during menstruation.

[0045] In some embodiments, the heat resistance temperature of the temperature and humidity sensitive microcapsule 200 is preferably greater than or equal to 150°C to ensure that it maintains high integrity in subsequent low-temperature coating and drying processes.

[0046] The dual-sensitivity response mechanism of the wall material 210 is as follows: When the ambient temperature is below 32℃, the composite material of PNIPAM and AR forms a dense cross-linked network, the micropores of the wall material 210 are closed, and the functional components in the core material 220 are difficult to release; when the temperature rises to 32-38℃, the PNIPAM molecular chain undergoes a segment conformational change and can absorb water and swell (the absorbed water comes from the moisture and water vapor emitted by human skin), the original dense cross-linked state begins to unfold, and the micropores of the wall material 210 are initially opened.

[0047] When the temperature is between 32 and 38°C, and the local humidity reaches or exceeds 55%RH, water molecules accelerate their penetration into the interior of the wall material 210. On the one hand, the large number of hydrophilic carboxyl groups in the acrylic resin absorb water and further swell the PNIPAM molecular chains, accelerating the expansion of micropores. On the other hand, water molecules form a hydrogen bond network with the acrylic resin, further reducing the intermolecular forces of the wall material 210, thereby enabling the core material 220 to begin to be effectively released within 30 seconds to 3 minutes.

[0048] Because the localized warm and humid environment formed on the surface of human skin can simultaneously provide a temperature of 32–38°C and a humidity of 55%RH, the sanitary analgesia chip can quickly release its functional ingredients when the sanitary product comes into contact with or adheres to the human body. Since the temperature and humidity-sensitive microcapsule 200 in this embodiment is triggered by a dual response of body temperature and local humidity, the sanitary analgesia chip in this embodiment can be effective even without menstrual blood before menstruation. Furthermore, the sanitary analgesia chip can be positioned closer to the uterus without needing to be moved downwards to contact menstrual blood.

[0049] The PNIPAM and AR materials form a three-dimensional cross-linked network using a divinylbenzene cross-linking agent. This network, along with the cross-linking network of PNIPAM and acrylic resin and the interactions between polymer chains, enhances the structural stability and heat resistance of the wall material 210. This allows the wall material 210 to withstand a heat resistance temperature exceeding 150°C and can withstand low-temperature coating processes below 130°C without thermal deformation or cracking within the body temperature response range. Although the local processing temperature in the low-temperature coating process may not exceed 130°C, the short processing duration and the absence of simultaneous temperature and humidity triggering conditions under usage conditions ensure that the microcapsules remain stably encapsulated and do not exhibit significant premature drug release.

[0050] The core material 220 of the temperature and humidity sensitive microcapsule 200 comprises multiple components, namely, phase change material, functional ingredients, transdermal penetration enhancer, and lipophilic agent. Based on 100% of the total mass of the core material 220, the mass fractions of each component are as follows: phase change material 25%, functional ingredients 63%, transdermal penetration enhancer 7%, and lipophilic agent 5%.

[0051] The phase change material is composed of n-tetradecane and n-hexadecane. The mass ratio of n-tetradecane to n-hexadecane is 7:3. The functional components include Corydalis extract, cinnamon extract, white peony extract, angelica extract, and motherwort extract. The mass fractions of Corydalis extract, cinnamon extract, white peony extract, angelica extract, and motherwort extract in the total mass of the core material 220 are 18%, 15%, 12%, 10%, and 8%, respectively.

[0052] The transdermal absorption enhancer is composed of menthol and laurocapram in a mass ratio of 1:2. Preferably, the transdermal absorption enhancer is a combination of menthol and laurocapram in a mass ratio of 1:2, as the synergistic effect of the two enhances transdermal absorption without causing skin irritation and shortens the onset time of the functional ingredients.

[0053] Among the functional ingredients, Corydalis extract, as the main analgesic component, can quickly inhibit pain signal transmission and relieve sharp and cramping pain; Cinnamon extract, as a warming and cold-dispelling component, can improve uterine cold pain with a gentle and lasting effect; White peony extract, as a smooth muscle spasm reliever, can relax uterine smooth muscle, inhibit spasms and cramps, and synergistically enhance the analgesic effect with Corydalis; Angelica extract and Leonurus extract, as blood-activating and menstrual-regulating components; Angelica extract improves the distension and dull pain caused by poor blood circulation and balances the overall medicinal properties; Leonurus extract assists in activating blood circulation, regulating menstruation, promoting diuresis and reducing swelling, and enhances the relief effect of menstrual discomfort. The components work together to form a compound effect of analgesia, warming the uterus, relieving spasms, and regulating menstruation. Furthermore, the functional ingredients have been optimized by removing weaker or non-targeting components, retaining only the five core functional components of analgesia, warming the uterus, relieving spasms, activating blood circulation, and regulating menstruation.

[0054] In some other embodiments, the mass fraction of the phase change material in the total mass of the core material 220 can be other values ​​within the range of 20% to 30% (e.g., 20%, 30%); the mass fraction of the transdermal penetration enhancer in the total mass of the core material 220 can be other values ​​within the range of 5% to 8% (e.g., 5%, 8%); the mass fraction of the Corydalis yanhusuo extract in the total mass of the core material 220 can be other values ​​within the range of 15% to 20% (e.g., 15%, 20%); the mass fraction of the cinnamon extract in the total mass of the core material 220 can be other values ​​within the range of 12% to 18% (e.g., 12%, 18%); the mass fraction of the white peony root extract in the total mass of the core material 220 can be other values ​​within the range of 10% to 15% (e.g., 10%, 15%); the mass fraction of the angelica sinensis extract in the total mass of the core material 220 can be other values ​​within the range of 8% to 12% (e.g., 8%, 12%); and the mass fraction of the motherwort extract in the total mass of the core material 220 can be other values ​​within the range of 5% to 10% (e.g., 5%, 10%). The amount of the lipophilic auxiliary agent, by weight, is any other value in the range of 7% to 10% of the amount of functional ingredients (i.e., the sum of the weights of the five extracts), such as 7%, 8%, 9%, or 10%.

[0055] In this embodiment, the functional components, based on the principles of "principal, assistant, adjuvant, and guide" in traditional Chinese medicine formulation, combine modern pharmacological synergistic effects, as follows:

[0056] The principal ingredient is Corydalis extract, which is primarily for pain relief and is the core analgesic component, accounting for the highest proportion and quickly relieving pain signals. The assistant ingredients are cinnamon extract and white peony extract, with cinnamon primarily warming the uterus and white peony primarily relieving spasms. Together, they assist Corydalis, with cinnamon providing a warming environment and white peony relaxing smooth muscles, thus doubly enhancing the analgesic effect. The adjuvant ingredients are Angelica sinensis extract and Leonurus japonicus extract, which invigorate blood circulation and regulate menstruation, improving blood circulation and relieving menstrual distension and dull pain from the root cause, preventing recurrence of pain. The guiding ingredients are phase change material and transdermal penetration enhancer. The phase change material creates a constant temperature environment to enhance the bioavailability of the active ingredients in traditional Chinese medicine, while the transdermal penetration enhancer accelerates the penetration of the ingredients, ensuring rapid onset of action.

[0057] The conclusions of the single-herb deficiency verification experiment are as follows: The absence of Corydalis extract decreased the dysmenorrhea relief rate, with no significant improvement in colic and sharp pain, indicating the failure of the core analgesic function; the absence of Cinnamon extract decreased the uterine cold pain relief rate, significantly reduced the effectiveness of premenstrual care, and failed to achieve uterine warming prevention; the absence of Paeonia lactiflora extract decreased the uterine smooth muscle spasm relief rate, with recurring menstrual cramps and a significantly reduced duration of analgesia; the absence of Angelica sinensis or Leonurus japonicus extract decreased the relief rate of distension and dull pain caused by poor blood circulation, increased the residual discomfort rate after menstruation, and indicated insufficient completeness of full-cycle care; the absence of phase change materials resulted in the disappearance of the constant temperature heat therapy effect, decreased transdermal absorption efficiency of traditional Chinese medicine, prolonged onset time, and a decreased overall relief rate.

[0058] The phase change material is a blend of n-tetradecane and n-hexadecane. The phase change temperature of n-tetradecane is approximately 35.8℃, and that of n-hexadecane is approximately 43.6℃. The blend forms a phase change temperature range of 32–38℃, which matches the temperature-sensitive triggering temperature range of the thermo-humidity-sensitive microcapsules 200. Furthermore, extracts of traditional Chinese medicine such as Angelica sinensis have a heating effect during absorption by the human body. The phase change material can maintain the local temperature within the phase change temperature range through its own phase change. The latent heat of phase change of the phase change material is preferably 180–200 J / g, which can maintain a constant temperature of 32–38℃ for the local area during use, and is conducive to the continuous diffusion and transdermal absorption of the traditional Chinese medicine components. The heat treatment temperature of 32–38℃ is close to the human skin temperature of 33–36℃, providing gentle heat treatment, promoting blood circulation, and relieving uterine smooth muscle spasms. The phase change material undergoes a solid-liquid phase transition at body temperature, which also improves the dispersion uniformity of the components within the core material 220 and prolongs the release time, resulting in an overall effective time of at least 8 hours. The phase change material composed of n-tetradecane and n-hexadecane meets the safety standards for feminine hygiene products, is non-toxic, and has no migration risk.

[0059] In some embodiments, the sanitary pain relief chip is used in conjunction with a self-heating ingredient integrated into feminine hygiene products. The self-heating ingredient provides heat to the body, and the phase change material prevents the heat temperature from exceeding 38°C, eliminating the risk of low-temperature burns.

[0060] In some embodiments, the five herbal extracts in the functional components are preferably prepared using a low-temperature water extraction and freeze-drying process.

[0061] The raw material of Corydalis rhizome is preferably dried goods free from mold, insects, sulfur, and impurities. It is first crushed and passed through a 10-mesh sieve, then 12 times the amount of purified water is added, and the mixture is extracted twice at 15-25℃, each time for 60 minutes. The extracts are combined and filtered through a plate and frame filter or centrifugation to remove residue. Then, the mixture is concentrated under reduced pressure at a temperature not exceeding 45℃ to a clear extract with a relative density of 1.06-1.10. The extract is then freeze-dried, and the freeze-dried blocks are crushed and passed through an 80-mesh sieve to obtain the Corydalis rhizome extract.

[0062] The cinnamon raw material is selected from herbs with strong aroma, free from mold, insect infestation, and scorch marks. After coarse crushing, it is passed through a 10-mesh sieve, and 12 times the amount of purified water is added. It is extracted twice at 15-25℃, 50 minutes each time. After filtration, it is concentrated at low temperature to a clear extract, freeze-dried, and pulverized through an 80-mesh sieve to obtain cinnamon extract.

[0063] After crushing the raw material of white peony powder through a 10-mesh sieve, add 12 times the amount of purified water and extract twice at 15-25℃ for 60 minutes each time. After filtration, low-temperature concentration, freeze-drying and passing through an 80-mesh sieve, the white peony extract is obtained.

[0064] Angelica sinensis raw material is sliced ​​and coarsely crushed, and 12 times the amount of purified water is added. It is extracted twice at 15-25℃, 60 minutes each time. After combining the filtrates, low-temperature concentration, freeze drying and pulverization through an 80-mesh sieve, Angelica sinensis extract is obtained.

[0065] The raw material of Leonurus japonicus was cut into sections and crushed, and 14 times the amount of purified water was added. It was extracted twice at 15-25℃ for 60 minutes each time. After filtration, low-temperature concentration, freeze-drying and passing through an 80-mesh sieve, the Leonurus japonicus extract was obtained.

[0066] In some embodiments, the freeze-drying conditions during the preparation of each extract are as follows: pre-freezing temperature -40°C and holding for 4 hours, sublimation drying temperature -10°C to 0°C and vacuuming to a pressure of 10Pa to 30Pa, and desorption drying temperature 25°C to 30°C until the moisture content is not higher than 3.0%. The 80-mesh pass rate of the resulting extract powder is preferably not less than 95%.

[0067] In this embodiment, the typical performance of the sanitary pain relief functional chip is as follows: the microcapsule integrity rate is preferably not less than 99.9%, the functional ingredient activity retention rate is preferably not less than 98%, the chip air permeability is preferably not less than 500mm / s, the surface friction coefficient is preferably not greater than 0.35, and it has no obvious irritation to the skin.

[0068] The feminine hygiene product chip provided in this embodiment adopts a separate design from the main feminine hygiene product. It does not participate in high-temperature spinning or withstand high-temperature processes above 200°C, thus ensuring the integrity and stability of the microcapsule and functional ingredients from a structural perspective.

[0069] The following five aspects were tested and verified on the sanitary pain relief chip provided in this embodiment:

[0070] 1. Dysmenorrhea relief rate: 100 women with moderate to severe dysmenorrhea were selected, 50 before menstruation and 50 during menstruation. The functional chip product was used for 3 consecutive cycles. The relief rate was evaluated using the visual analog scale (VAS) method. The relief rate was calculated by dividing the difference between the pre-treatment score and the post-treatment score by the pre-treatment score and then multiplying by 100%. The pre-treatment relief rate was 88%, and the menstrual relief rate was 93%, both of which met the target requirements.

[0071] 2. Skin irritation reaction: According to GB / T 16886.5-2017 "Skin irritation test for medical devices", the functional chip was subjected to skin irritation test. Skin erythema and edema were observed at 24 hours and 48 hours respectively. The test result was grade 0, which means no irritation and meets the safety standards for feminine hygiene products.

[0072] 3. Skin sensitization reaction: According to GB / T 16886.10-2017 "Skin sensitization test for medical devices", skin sensitization test was conducted and observed for 14 consecutive days. The sensitization reaction was negative and there was no risk of sensitization.

[0073] 4. Air permeability: The YG461E air permeability tester was used to test the air permeability according to GB / T 5453-1997 "Test for air permeability of textiles". The test result is greater than or equal to 500 mm / s, which meets the requirements for breathability and comfort.

[0074] 5. Implementation Standards: The products strictly comply with GB 15979-2024 "Standard for Disposable Hygiene Products" and YY / T0691 "Protective Equipment for Infectious Pathogens" standards, and have a shelf life of 3 years or more.

[0075] Example 2

[0076] A method for preparing a temperature and humidity-responsive sanitary analgesia functional chip, used to prepare the functional chip provided in Example 1.

[0077] like Figure 3 As shown, the preparation method includes the following steps:

[0078] Step 1: Preparation of Core Material 220 Premix: Since the five herbal extracts are typically hydrophilic powders after freeze-drying, to ensure their entry into the oil phase of the microcapsule and prevent leakage during emulsification and polymerization, this embodiment includes a core material 220 pretreatment step before microcapsule preparation. Specifically, the freeze-dried powders of Corydalis Rhizome Extract, Cinnamon Extract, White Peony Root Extract, Angelica Root Extract, and Leonurus Herb Extract are mixed evenly according to a preset ratio. 7%–10% of glyceryl monostearate or beeswax is added, and the mixture is melt-stirred at 55–65°C for 30 minutes to achieve a hydrophilic coating on the surface of the herbal extracts, forming a uniform hydrophilic complex. After cooling to room temperature, it is mixed with a phase change material and a transdermal penetration enhancer to form a core material 220 premix, which includes a uniformly mixed phase change material, herbal extracts, and transdermal penetration enhancer. This premix is ​​then kept at 30°C for later use to prevent stratification.

[0079] In some embodiments, the phase change material is preferably heated to its melting temperature before being mixed with the oleophilic compound to improve the uniformity of the core material 220 premix.

[0080] In this embodiment, top-grade ingredients from traditional Chinese medicine for external use, including those for relieving pain, warming the uterus, relieving spasms, and regulating menstruation, were selected as the functional ingredients. Combined with ultrasound-assisted high-efficiency extraction technology, a high-purity, high-activity, safe, and highly transdermal compound extract system was constructed to achieve rapid relief and long-lasting soothing for dysmenorrhea.

[0081] Step 2: Prepare temperature and humidity sensitive microcapsules 200.

[0082] (1) Preparation of the aqueous phase system: By mass, take 50 parts of deionized water, 2 parts of polyvinyl alcohol (PVA), 0.5 parts of sodium dodecyl sulfate (SDS), and 10 parts of N-isopropylacrylamide (PNIPAM monomer), add them to a reaction vessel and stir to dissolve. Control the water temperature at 30°C to obtain a stable aqueous phase system. The polyvinyl alcohol is specifically type 1788 polyvinyl alcohol, which is used as an emulsifying stabilizer in this embodiment. The sodium dodecyl sulfate is used as a co-emulsifier in this embodiment. In some further preferred embodiments, the aqueous phase system is prepared in the following order: first, PVA is added to heated deionized water and dissolved completely, then SDS is added after cooling, and finally PNIPAM monomer is added.

[0083] (2) Preparation of the oil phase system: Take 30 parts of methyl acrylate (MA, acrylic resin monomer), 5 parts of divinylbenzene (DVB), 0.5 parts of azobisisobutyronitrile (AIBN), and 20 parts of core material 220 premix, and stir at 1000 rpm for 10 minutes to form a homogeneous oil phase system; in this embodiment, the divinylbenzene is used as a crosslinking agent to improve the heat resistance of wall material 210. In this embodiment, the azobisisobutyronitrile is used as an initiator.

[0084] (3) Emulsification and dispersion: The above oil phase system is slowly added dropwise to the aqueous phase system, preferably with a dropping rate of 5 mL / min, and the temperature is maintained at 30°C throughout the process; high shear stirring is performed for 30 minutes to form an O / W type emulsion, and the median particle size D50 of the emulsion is preferably controlled between 1 and 3 μm. In some embodiments, the stirring speed can be increased to about 1500 rpm to further improve the particle size uniformity.

[0085] (4) Polymerization to generate wall material 210: The emulsion obtained in step (3) is transferred to a polymerization reactor. Nitrogen gas is first purged for protection for 10 minutes, and then the temperature is increased to 60°C (in some other embodiments, other values ​​between 55°C and 70°C can be used) and kept at that temperature for 4 hours, so that wall material 210 undergoes a polymerization reaction at the oil-water interface to form AR-PNIPAM composite material. Nitrogen protection helps to reduce the adverse effects of oxygen on the polymerization reaction and is one of the important process control points for the stable preparation of microcapsules in this embodiment.

[0086] (5) Post-processing: After polymerization, cool to room temperature, centrifuge at 3000-5000 rpm, wash 3 times to remove unreacted monomers, wash once with anhydrous ethanol to remove residual oil phase, and then vacuum dry at 40°C for 12 hours to obtain temperature and humidity sensitive microcapsules 200 product.

[0087] In this embodiment, the mass ratio of methyl acrylate to N-isopropylacrylamide as monomers is 3:1. This ratio optimizes the temperature-sensitive and heat-resistant properties, ensuring that the microcapsules respond within the range of 32 to 38°C. The amount of crosslinking agent is 5% to 8% of the total mass of monomers. Insufficient crosslinking agent will result in poor heat resistance of the wall material 210, while excessive amount will reduce the response sensitivity. The emulsion system uses a blend of PVA and SDS in a mass ratio of 4:1. This system can ensure emulsion stability, avoid microcapsule aggregation, and ensure that the microcapsule particle size uniformity is greater than or equal to 90%.

[0088] Step 3: Prepare the coating stock solution.

[0089] After preparing the temperature and humidity sensitive microcapsules 200, 10-20 parts by weight of the temperature and humidity sensitive microcapsules 200, 3-8 parts by weight of the aqueous binder, 1-2 parts by weight of the skin-friendly additive, and the remainder of deionized water are mixed and dispersed to form a coating masterbatch. The aqueous binder is preferably hydroxypropyl methylcellulose HPMC (E50 type), and the skin-friendly additive is preferably glyceryl monostearate. The stirring speed is controlled at 800-1000 rpm, and the stirring time is approximately 15 minutes to avoid high-speed shearing causing damage to the microcapsules.

[0090] Step 4: Prepare functional chip rolls.

[0091] The coating masterbatch is quantitatively coated onto the surface of ES plain white hot air nonwoven fabric substrate 100 using a slit-type coating machine. The preferred coating speed is 5-10 m / min; the coating amount is 5-20 g / m. 2 Preferably, it is 10-15 g / m 2 Further optimization of 12g / m 2 In some embodiments, the obtained functional chip roll is dried in three stages. The first stage pre-drying temperature is 50-60°C for 1 minute; the second stage main drying temperature is 80-90°C for 3 minutes; and the third stage curing temperature is 100-120°C for 2 minutes. The drying air velocity is preferably 2-3 m / s (to prevent excessive air velocity from causing microcapsules to migrate on the surface of the substrate 100), and the temperature throughout the process does not exceed 130°C (to prevent the microcapsule wall material 210 from softening, cracking, or premature drug release). After drying, the roll is cooled, cured, and wound up to obtain the functional chip roll.

[0092] In some embodiments, the integrity rate of microcapsules in the obtained functional chip roll is not less than 99.9%, and the retention rate of functional components is not less than 98%.

[0093] Step 5: Functional Chip Molding: The functional chip roll obtained in Step 4 is processed into the desired shape using a laser die-cutting process to obtain a sanitary pain relief functional chip. In this embodiment, the die-cutting speed is 8-12 times / minute, the die-cutting pressure is 0.3-0.5 MPa, and an integrity test is performed after die-cutting, with a breakage rate not exceeding 0.1%. The resulting functional chip can be triangular, rectangular, circular, or square, and is preferably placed in sanitary products corresponding to the lower abdomen of the human body, i.e., the uterine region in women.

[0094] The sanitary pain relief chip prepared in this embodiment has the following typical performance characteristics: the microcapsule integrity rate is preferably not less than 99.9%, and the functional ingredient activity retention rate is preferably not less than 98%; the chip air permeability is preferably not less than 500 mm / s, and the surface friction coefficient is preferably not greater than 0.35; under actual use conditions, the chip can be triggered to release under the combined action of human body temperature and local humidity, meeting the pain relief care needs of the premenstrual and menstrual periods.

[0095] To verify the formation of the sanitary analgesia functional chip prepared in this embodiment, a constant temperature and humidity chamber, a laser particle size analyzer, and a high-performance liquid chromatograph were used to characterize the release time, porosity, and release amount of functional components under conditions of 32℃, 35℃, 38℃ and 60%RH, 70%RH, and 80%RH, in order to verify its dual-sensitivity response performance. The specific process and results are as follows:

[0096] 1. Experimental Objective

[0097] The study aimed to verify the auto-opening characteristics, opening rate, and component release patterns of microcapsules under body temperature ranges of 32 to 38°C and humidity conditions of 60% to 80% RH.

[0098] 2. Experimental Equipment and Materials

[0099] The experimental equipment included a constant temperature and humidity chamber (temperature control accuracy ±0.1℃, humidity control accuracy ±2%RH), a laser particle size analyzer, a high performance liquid chromatograph, and an electronic balance (accuracy 0.0001 g); the experimental materials were the temperature and humidity sensitive microcapsules 200 prepared in this embodiment, deionized water, phase change materials, and traditional Chinese medicine extract standards.

[0100] 3. Experimental Grouping and Conditions

[0101] Three temperature gradients were set up: 32℃, 35℃, and 38℃, and three humidity gradients: 60%RH, 70%RH, and 80%RH. A total of nine experiments were conducted, with each group repeated three times, and the average value was taken.

[0102] 4. Experimental Procedures and Data Recording

[0103] (1) Functional component release time and open porosity test

[0104] Take 0.1 g of microcapsules, disperse them evenly on a glass slide, and place them in a constant temperature and humidity chamber for the corresponding group. Use a laser particle size analyzer to monitor the microcapsule particle size change in real time. When the microcapsule particle size expands from 1 to 3 micrometers to 5 to 8 micrometers, it is determined to be fully open-celled. Record the release time of the functional component. The formula for calculating the open-cell rate is the number of fully open-celled microcapsules divided by the total number of microcapsules and then multiplied by 100%. The test duration is 10 minutes.

[0105] (2) Component release test

[0106] After treating the microcapsules under the above conditions for 10 minutes, rinse the surface of the microcapsules with 5 ml of deionized water and collect the eluent. Use high performance liquid chromatography to detect the content of Corydalis extract, cinnamon extract and phase change material in the eluent, and calculate the component release per unit mass of microcapsules, in μg / g.

[0107] (3) Experimental data recording

[0108] In the first group, the temperature was 32℃ and the humidity was 60%RH. The release time of the functional components was 180±15 seconds, the release amount of Corydalis was 12±2μg / g, and the release amount of Cinnamon was 8±1μg / g.

[0109] In the second group, the temperature was 32℃ and the humidity was 70%RH. The release time of the functional components was 120±10 seconds, the release amount of Corydalis was 28±3μg / g, and the release amount of Cinnamon was 15±2μg / g.

[0110] In the third group, at a temperature of 32℃ and a humidity of 80%RH, the release time of the functional components was 90±8 seconds, the release amount of Corydalis was 45±4μg / g, and the release amount of Cinnamon was 28±3μg / g.

[0111] In the fourth group, at a temperature of 35℃ and a humidity of 60%RH, the release time of the functional components was 150±12 seconds, the release amount of Corydalis was 22±3μg / g, and the release amount of Cinnamon was 12±2μg / g.

[0112] Group 5, temperature 35℃, humidity 70%RH, functional component release time was 80±7 seconds, corydalis release amount was 52±5μg / g, cinnamon release amount was 32±3μg / g.

[0113] In the sixth group, at a temperature of 35℃ and a humidity of 80%RH, the release time of the functional components was 60±6 seconds, the release amount of Corydalis was 68±6μg / g, and the release amount of Cinnamon was 45±4μg / g.

[0114] Group 7, temperature 38℃, humidity 60%RH, functional component release time 120±10 seconds, corydalis release amount 30±3μg / g, cinnamon release amount 18±2μg / g.

[0115] Group 8, temperature 38℃, humidity 70%RH, functional component release time 50±5 seconds, corydalis release amount 65±6μg / g, cinnamon release amount 40±4μg / g.

[0116] Group 9, temperature 38℃, humidity 80%RH, functional component release time was 40±4 seconds, corydalis release amount was 82±7μg / g, cinnamon release amount was 50±5μg / g.

[0117] The release amounts mentioned above refer to the release mass of each herbal component relative to the mass of the Wenshi Shuangmin microcapsule 200. For example, a release amount of 12±2μg / g for Corydalis means that 12±2μg of Corydalis is released per gram of Wenshi Shuangmin microcapsule 200.

[0118] Example 3

[0119] like Figure 4 As shown, a temperature and humidity-responsive sanitary pain relief chip is disclosed. The difference between this embodiment and Embodiment 1 is that the sanitary pain relief chip further includes a breathable, skin-friendly contact layer 300 and an anti-migration isolation layer 400. The breathable, skin-friendly contact layer 300 and the anti-migration isolation layer 400 respectively cover both sides of the substrate 100. The breathable, skin-friendly contact layer 300, the substrate 100, and the anti-migration isolation layer 400 are stacked sequentially and fixed at their edges. The breathable, skin-friendly contact layer 300 ensures contact comfort and breathability. The substrate 100, loaded with temperature and humidity-sensitive microcapsules 200, serves as the core active layer. The anti-migration isolation layer 400 prevents the functional components from migrating downwards to the absorbent core 700, promoting the release of the functional components primarily towards the skin.

[0120] The breathable and skin-friendly contact layer 300 is preferably made of one of the following: soft and breathable hot-air nonwoven fabric, spunbond nonwoven fabric, or perforated film; the anti-migration isolation layer 400 is preferably made of one of the following: dense film, water-repellent nonwoven fabric, or composite isolation layer with directional transmission function.

[0121] The breathable and skin-friendly contact layer 300, the substrate 100, and the anti-migration isolation layer 400 can be fixedly connected by a low-temperature composite method. Preferably, the interlayer composite is achieved by edge hot pressing, dot bonding, or water-based adhesive bonding to avoid damaging the structure of the temperature and humidity sensitive microcapsule 200.

[0122] During the preparation process, the raw material rolls of the breathable and skin-friendly contact layer 300 and the raw material rolls of the anti-migration isolation layer 400, and the functional chip rolls obtained in step four are stacked and processed into the required shape by laser die-cutting process to obtain the sanitary pain relief functional chip.

[0123] The anti-migration isolation layer 400 is located on the side of the substrate 100 away from the skin, and is used to reduce the probability of functional ingredients migrating downward to the absorbent core; the breathable and skin-friendly contact layer 300 is located on the side of the substrate 100 close to the skin, and is used to improve contact comfort and breathability, making it easier for functional ingredients to be released towards the skin.

[0124] In some embodiments, the breathable and skin-friendly contact layer 300, the substrate 100, the temperature and humidity sensitive microcapsules 200 and the anti-migration isolation layer 400 are composited into one piece by a low-temperature coating and curing process, resulting in a thin and soft overall product with a total thickness of ≤0.3mm, which does not affect the overall wearing experience of the hygiene products.

[0125] The three-layer structure described in this embodiment not only ensures comfort but also improves the directional utilization rate of functional components and reduces the loss caused by the adsorption of functional components by the absorption core 700.

[0126] The sanitary pain relief chip provided in this embodiment has the characteristics of high breathability, low friction, skin-friendly and non-irritating, and non-allergenic, and fully meets the highest safety standards for feminine hygiene products.

[0127] Example 4

[0128] like Figure 5 As shown, a sanitary napkin includes a surface layer 500, a diversion layer 600, an absorbent core 700, a leak-proof layer 800, a bottom film layer 900, and a sanitary napkin pain-relieving functional chip provided in Example 1. The surface layer 500, diversion layer 600, absorbent core 700, leak-proof layer 800, and bottom film layer 900 are sequentially stacked. The sanitary napkin pain-relieving functional chip is disposed between the surface layer 500 and the diversion layer 600.

[0129] In some embodiments, the flow-guiding layer 600 is partially or entirely provided with a self-heating component. The self-heating component is a conventional heating material that provides localized heating to the human body. In some further embodiments, the self-heating component is natively integrated into the flow-guiding layer. In some further embodiments, the self-heating component is only disposed on the flow-guiding layer 600 at a position aligned with the pain-relieving functional chip.

[0130] Example 5

[0131] like Figure 6As shown, a sanitary napkin includes a surface layer 500, a diversion layer 600, an absorbent core 700, a leak-proof layer 800, a bottom film layer 900, and a sanitary napkin comfort chip provided in Example 3. The surface layer 500, diversion layer 600, absorbent core 700, leak-proof layer 800, and bottom film layer 900 are stacked sequentially. The sanitary napkin comfort chip is disposed between the surface layer 500 and the diversion layer 600. In the sanitary napkin comfort chip, the anti-migration isolation layer 400 is located on the side of the substrate 100 near the diversion layer 600. The breathable and skin-friendly contact layer 300 is located on the side of the substrate 100 near the surface layer 500. The breathable and skin-friendly contact layer 300 ensures contact comfort and breathability. The anti-migration isolation layer 400 prevents functional ingredients from migrating downwards to the absorbent core 700, promoting the release of functional ingredients primarily towards the skin.

[0132] Example 6

[0133] A menstrual panty includes a top layer, a fluid-absorbing layer, a leak-proof membrane, and an elastic panty body, arranged in layers from the inside out. A sanitary pain-relieving functional chip, as provided in Embodiment 1 or 3, is disposed between the top layer and the fluid-absorbing layer.

Claims

1. A warm and humid dual-response functional chip for relieving pain in the urinary system, comprising a substrate; characterized in that, It also includes temperature and humidity sensitive microcapsules loaded on the substrate; the temperature and humidity sensitive microcapsules include a core material and a wall material wrapped around the outside of the core material; the wall material is a composite material of acrylic resin and poly(N-isopropylacrylamide); the core material includes functional components.

2. The functional chip of claim 1, wherein, The core material also includes a phase change material; the phase change temperature range of the phase change material is 32–38°C.

3. The functional chip of claim 1, wherein, The core material also includes transdermal penetration enhancers; the transdermal penetration enhancers include menthol and laurocapram; the functional components include Corydalis extract, cinnamon extract, white peony extract, angelica extract and motherwort extract in a mass ratio of (15-20):(12-18):(10-15):(8-12):(5-10).

4. The functional chip of claim 1, wherein, The acrylic resin and poly(N-isopropylacrylamide) in the wall material form a three-dimensional cross-linked network through a cross-linking agent.

5. The functional chip for toilet use according to claim 1, wherein It also includes a breathable and skin-friendly contact layer and an anti-migration isolation layer; the substrate is disposed between the breathable and skin-friendly contact layer and the anti-migration isolation layer; the substrate has temperature and humidity sensitive microcapsules only on the side near the breathable and skin-friendly contact layer or on both sides.

6. A method of manufacture, characterized by, Used to prepare the sanitary analgesia functional chip as described in any one of claims 1 to 4; The preparation method includes: Preparation of core material premix: The freeze-dried powders of Corydalis extract, cinnamon extract, white peony extract, angelica extract and motherwort extract are mixed in a preset ratio, an oleophilic auxiliary is added, and after cooling, they are mixed with phase change material and transdermal accelerator to obtain core material premix. Preparation of temperature and humidity sensitive microcapsules: An aqueous phase system was prepared using polyvinyl alcohol and sodium dodecyl sulfate, and an oil phase system was prepared using methyl acrylate monomer, N-isopropylacrylamide monomer, divinylbenzene, azobisisobutyronitrile and core material premix. The oil phase system was added dropwise to the aqueous phase system to form an emulsion, and the mixture was heated to carry out a polymerization reaction. Nitrogen gas was continuously introduced during the polymerization reaction. After the polymerization reaction, the microcapsules were cooled, centrifuged, washed, and vacuum dried to obtain the temperature and humidity sensitive microcapsules. Preparation of coating stock solution: Mix the temperature and humidity sensitive microcapsules, aqueous adhesive, skin-friendly additive and deionized water to obtain the coating stock solution; Preparation of functional chip roll material: The coating masterbatch is coated on the surface of the substrate, dried, cooled and then rolled up to obtain the functional chip roll material; Functional chip molding: Processing functional chip rolls into pre-defined shapes for sanitary pain relief functional chips.

7. The preparation method according to claim 6, characterized in that, The lipophilic agent is glyceryl monostearate or beeswax; the amount of the lipophilic agent is 8% to 10% of the total mass of each extract; after adding the lipophilic agent, the mixture is stirred at 55 to 65°C.

8. The preparation method according to claim 6, characterized in that, During the process of adding the oil phase system to the aqueous phase system, an emulsion with a median particle size D50 of 1 to 3 μm is formed through shear emulsification; the aqueous adhesive is hydroxypropyl methylcellulose, and the skin-friendly auxiliary agent is glyceryl monostearate.

9. A sanitary article, characterized in that The product includes a sanitary product body and a sanitary pain relief chip as described in any one of claims 1-5, which is installed inside the sanitary product; the sanitary product body is any one of sanitary napkins, panty liners, menstrual pants, or uterine warming care patches; when the sanitary product is in use, the sanitary pain relief chip is aligned with the lower abdomen of the human body.

10. A sanitary napkin characterized by It includes a surface layer, a flow-guiding layer, an absorbent core, a waterproof layer, and the sanitary pain relief functional chip as described in claim 5; the surface layer, flow-guiding layer, absorbent core, and waterproof layer are stacked in sequence, and the sanitary pain relief functional chip is disposed between the surface layer and the flow-guiding layer; the anti-migration isolation layer is located on the side of the substrate near the flow-guiding layer, and the breathable and skin-friendly contact layer is located on the side of the substrate near the surface layer.

Images